#China #Hong Kong #Fosun International #financial report #Fosun Pharma

Fosun International's Strong Financial Performance and Strategy for Future Growth

On March 30, 2026, Fosun International (stock code: 00656.HK) shared its impressive financial results for the twelve months ended December 31, 2025. The company’s total revenue reached a staggering RMB173.43 billion, showcasing robust growth trends fueled by its core sectors such as pharmaceuticals, healthcare, and finance. With overseas revenue accounting for 54.7% of its total earnings, this figure marks a notable year-on-year increase.

Solid Foundations: Core Segments Drive Growth

During the reporting period, Fosun's core subsidiaries, which include Fosun Pharma and Fosun Insurance Portugal, significantly contributed to its financial performance. Together, these subsidiaries generated RMB128.2 billion in revenue, representing 74% of the group's total revenue. Fosun Pharma alone reported a 21.69% increase in net profit, amounting to RMB3.371 billion, while Fosun Insurance Portugal attained a profit of EUR201 million, up 15.8% from the previous year.

Fosun's commitment to innovation is evident, with an investment of RMB7.8 billion in technological advancements. In 2025, 16 indications for seven innovative drugs received marketing approval, highlighted by nearly 40 innovative drug clinical trials authorized in major markets such as China, the United States, and Europe.

Emphasizing Global Expansion and Strategic Focus

The global revenue growth reflects Fosun's strategic emphasis on expanding its international presence. Total overseas revenue climbed to RMB94.86 billion, increasing by 5.4 percentage points compared to the prior year. Significant actions in licensing-out and co-development of innovative drugs yielded over USD260 million in initial payments, signaling the company's deep engagement in the global pharmaceutical landscape.

Moreover, Fosun’s leisure segment, notably Club Med, achieved record performance, underlining the group's diversified portfolio. Despite facing challenges from certain real estate projects that necessitated non-cash impairment provisions, the company’s overall financial health remains stable, supported by significant cash reserves and a strong net asset base.

A Pragmatic Approach for Future Stability and Growth

In a letter to shareholders, Chairman Guo Guangchang emphasized the necessity of addressing asset valuations in light of current market conditions. By prudently choosing to finalize asset impairments, Fosun can better concentrate on high-growth sectors, thereby optimizing its asset structure. Guo expressed optimism about Fosun's ability to maneuver through market fluctuations by reinforcing its strategic focus, which would ultimately lead to sustainable growth.

As part of its ongoing strategy, Fosun outlined medium-term financial targets, including a drive to restore annual profits to around RMB10 billion and to reduce Group-level debt to below RMB60 billion. Enhancing shareholder returns is also a priority, with plans to increase the dividend payout ratio for the 2026 financial year from 20% to 35%.

Guo’s commitment aligns Fosun on a path toward enduring growth, emphasizing that the company will not focus on immediate returns but rather on building a solid foundation for long-term success.

With a stable credit rating outlook and strong financial indicators, Fosun International is set to navigate the complexities of the global market while seizing strategic opportunities for growth and development in its core business sectors.